InTest Corporation heads into its Q1 2026 earnings call — scheduled for May 4 — with options sentiment at its most bullish in months, the stock up sharply on a one-month view, and a cluster of insider selling in the rear-view mirror.
The clearest market signal right now is in options. Traders have moved decisively toward calls, pushing the put/call ratio to just 0.058 — well below its 20-day average of 0.108 and near the bottom of the 52-week range. That's almost 1.6 standard deviations below the recent mean, indicating pronounced call-side demand. The shift has been rapid: six weeks ago the PCR was running above 0.14, consistent with more cautious positioning. Whatever drove the downside protection demand through March and early April has largely unwound.
The price story supports that rotation. INTT closed Wednesday at $16.76, essentially flat on the week but up nearly 20% over the past month. The stock's YTD gain now exceeds 139%, a remarkable run for a micro-cap semiconductor equipment name with a market cap around $220 million. Short interest is not the story here — it amounts to just 0.6% of the free float, with fewer than 75,000 shares short. That level is too small to drive or explain much. Availability in the lending market is ample, and cost to borrow, at 3.0%, has nearly doubled over the week but remains modest in absolute terms. The borrow market is calm.
The Street's positioning is a study in caution-meets-momentum. The only analyst action current enough to cite is Lake Street's March 2 move, which lifted the price target to $19 from $10 while maintaining a Buy rating — a sharp upward revision coming just days after what turned out to be a strong earnings print. The consensus mean target of roughly $17.67 is barely above the current price. That means the formal analyst community is only marginally constructive from here, even after the post-earnings re-rating. The DTC rank scores at the 87th percentile and EPS momentum on a 90-day basis ranks at the 84th percentile — both solid readings. But without fresher analyst updates, the Street signal is more of a datapoint than a driver.
The insider picture is more pointed. Between March 6 and March 18, CEO Richard Grant sold 4,130 shares across three transactions at prices between $13.24 and $14.28. Several division presidents — McManus, Rogoff, and Goodrich — also trimmed small positions across the same period, though at nominal values under $5,000 each. A fresh Form 4 filed on April 29 for Rogoff Richard B covers an April 28 date, suggesting the selling activity has continued into late April. The net 90-day insider position is a sale of roughly $79,000. The sales followed an equity award to Rogoff on March 17, which provides partial context — but the CEO's consistent drip-selling into a rising stock at multiples above the prior trade prices is worth tracking.
The earnings history sharpens the stakes for May 4. The Q4 print in late February produced a 22% single-day gain and a 32.5% five-day gain — one of the more violent post-earnings moves seen in any micro-cap this year. The March 2 event (likely a follow-on analyst day or further earnings-related announcement) added another 5% on the day and 16.7% over five days. That sequence of strong reactions has directly funded the current option-call positioning. The question heading into next week's Q1 release is whether the underlying business momentum can justify what has become a 34x trailing PE on a stock that, until February, was priced for decline.
What to watch: whether the May 4 earnings call delivers revenue and guidance consistent with the optimism already priced into call positioning — and whether the CEO's ongoing share sales accelerate after any further price strength following the print.
See the live data behind this article on ORTEX.
Open INTT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
